ERBB2 and non-small cell lung carcinoma: In two Chinese phase II trials in pre-treated HER2 MUT (Ex20/others) NSCLC patients treated with pyrotinib, ORRs ranged from 19 to 53%, mPFS ranged from 5.6 to 6.4 months, and mOS ranged from 10.5 to 12.9 months [72,73].